DE69942365D1 - Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben - Google Patents

Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben

Info

Publication number
DE69942365D1
DE69942365D1 DE69942365T DE69942365T DE69942365D1 DE 69942365 D1 DE69942365 D1 DE 69942365D1 DE 69942365 T DE69942365 T DE 69942365T DE 69942365 T DE69942365 T DE 69942365T DE 69942365 D1 DE69942365 D1 DE 69942365D1
Authority
DE
Germany
Prior art keywords
binding domain
fusion polypeptide
collagen binding
nucleic acid
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942365T
Other languages
English (en)
Inventor
Frederick L Hall
Erlina M Gordon
Vaughn A Starnes
W French Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE69942365D1 publication Critical patent/DE69942365D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
DE69942365T 1998-07-31 1999-07-30 Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben Expired - Lifetime DE69942365D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/127,134 US6387663B1 (en) 1998-07-31 1998-07-31 Targeting pharmaceutical agents to injured tissues
PCT/US1999/017297 WO2000006195A1 (en) 1998-07-31 1999-07-30 Targeting pharmaceutical agents to injured tissues

Publications (1)

Publication Number Publication Date
DE69942365D1 true DE69942365D1 (de) 2010-06-24

Family

ID=22428477

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942365T Expired - Lifetime DE69942365D1 (de) 1998-07-31 1999-07-30 Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben

Country Status (11)

Country Link
US (2) US6387663B1 (de)
EP (1) EP1100535B1 (de)
JP (1) JP4564657B2 (de)
AT (1) ATE467425T1 (de)
AU (1) AU758483B2 (de)
CA (1) CA2337979A1 (de)
DE (1) DE69942365D1 (de)
ES (1) ES2346275T3 (de)
IL (3) IL141141A0 (de)
NZ (1) NZ509804A (de)
WO (1) WO2000006195A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE316980T1 (de) * 1999-07-21 2006-02-15 Univ Southern California Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
CA2400319C (en) * 2000-03-15 2008-09-16 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20040053368A1 (en) * 2000-08-15 2004-03-18 Tetsuya Ishikawa Collagen-binding hybrid polypeptide
WO2002030443A2 (en) * 2000-10-11 2002-04-18 The Wistar Institute Regulation of human skin healing
ES2186501B1 (es) * 2000-11-23 2006-05-16 Universidad De Malaga Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
WO2003018752A2 (en) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
WO2005003317A2 (en) * 2003-07-01 2005-01-13 Regents Of The University Of Minnesota Engineered blood vessels
EP1924606A4 (de) * 2005-08-25 2010-01-13 Repair Technologies Inc Vorrichtungen, zusammensetzungen und verfahren zum schutz und zur reparatur von zellen und gewebe
ATE514712T1 (de) 2005-12-26 2011-07-15 Yantai Zhenghai Bio Technology Co Ltd Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren
JP2009540936A (ja) 2006-06-22 2009-11-26 ユニバーシティー オブ サウス フロリダ コラーゲン足場、それを伴う医療用埋植物、およびその使用方法
DE102007010306A1 (de) * 2007-02-22 2008-08-28 Eberhard-Karls-Universität Tübingen Universitätsklinikum Bispezifisches Fusionsprotein mit therapeutischem und diagnostischem Potenzial
CA2930681C (en) 2007-04-09 2019-10-15 The Board Of Trustees Of The University Of Arkansas Fusion protein of collagen-binding domain and parathyroid hormone
JP5260976B2 (ja) * 2008-02-08 2013-08-14 東ソー株式会社 血液凝固第ｖｉｉｉ因子ｃ２ドメインタンパク質の製造方法
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN101671396B (zh) * 2008-09-11 2012-07-18 烟台正海生物技术有限公司 与胶原蛋白特异结合的血管内皮生长因子及其应用
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
SG187018A1 (en) * 2010-07-19 2013-02-28 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
US9173919B2 (en) 2011-02-16 2015-11-03 Purdue Research Foundation Collagen-targeted nanoparticles
CA2859412C (en) 2011-12-14 2021-05-25 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
US10420820B2 (en) 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
CN106188306B (zh) * 2015-05-04 2020-07-24 北京同建再生医学技术有限公司 治疗性重组抗体、其编码基因及应用
EP3355907B1 (de) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bispezifische therapeutische proteine zur gewebereparatur
WO2017218355A1 (en) 2016-06-15 2017-12-21 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
US20200331984A1 (en) * 2016-09-20 2020-10-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface
US10913779B2 (en) 2017-01-25 2021-02-09 Counterpoint Biomedica Llc Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
CN109125710A (zh) * 2017-06-15 2019-01-04 中国科学院遗传与发育生物学研究所 胶原靶向血管内皮生长因子在陈旧性心肌梗死治疗中的应用
EP3762429A4 (de) 2018-03-09 2022-03-23 University of Pittsburgh - Of the Commonwealth System of Higher Education Abgabe von biologischen wirkstoffen an gewebe
BR112021007175A2 (pt) 2018-10-23 2021-08-10 Dragonfly Therapeutics, Inc. proteínas fundidas a fc heterodimérico
JP2022542886A (ja) * 2019-07-25 2022-10-07 ザ・ユニバーシティ・オブ・シカゴ プロテアーゼ活性化治療剤を含む組成物および方法
CN113121700B (zh) * 2019-12-30 2023-06-13 独步吾奇生物医疗科技(江苏)有限公司 与胶原特异结合的重组蛋白、其编码基因及应用
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
WO2022256568A1 (en) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751179T2 (de) * 1986-05-30 1995-07-27 Scripps Research Inst Peptide, die die Bindung des Von-Willebrand-Faktors inhibieren.
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
ES2303726T3 (es) * 1997-04-10 2008-08-16 University Of Southern California Proteinas modificadas que se fijan a componentes de la matriz extracelular.
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions

Also Published As

Publication number Publication date
JP2002521044A (ja) 2002-07-16
EP1100535A1 (de) 2001-05-23
IL141141A (en) 2008-07-08
WO2000006195A1 (en) 2000-02-10
NZ509804A (en) 2003-07-25
IL190793A0 (en) 2008-11-03
US20020164719A1 (en) 2002-11-07
EP1100535A4 (de) 2004-12-29
US6387663B1 (en) 2002-05-14
EP1100535B1 (de) 2010-05-12
JP4564657B2 (ja) 2010-10-20
ATE467425T1 (de) 2010-05-15
AU5328699A (en) 2000-02-21
ES2346275T3 (es) 2010-10-13
CA2337979A1 (en) 2000-02-10
US6955898B2 (en) 2005-10-18
AU758483B2 (en) 2003-03-20
IL141141A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
ATE393831T1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DK0910647T3 (da) Human DNase i hyperaktive varianter
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
PT923570E (pt) Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos
DE69941576D1 (de) Antisense-modulation der survivin-expression
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
ATE337339T1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
DE60025830D1 (de) Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DK0994884T3 (da) Diphosphonsyresalte til behandling af osteoporose
NO982181L (no) Type IX collagen og chimerer
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
ATE362531T1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition